Azole derivatives and fused bicyclic azole derivatives as therapeutic agents

A compound of Formula (Ib)

• wherein
• R1 is -hydrogen, -alkyl, or -alkenyl,
• R3 is -hydrogen or -alkyl;
• and
• R102 and R104 are independently selected from the group consisting of:
• a) —H;
• b) -alkyl;
• c) -aryl;
• d) -heteroaryl;
• e) -alkylene-heteroaryl-aryl;
• f) -alkylene-aryl;
• g) -alkylene-W2—R18;
• h) —Y4—NR23R24;
• i) —Y4—NH—C(═NR25)NR23R24;
• j) —Y4—C(═NR25)NR23R24;
• and
• k) —Y4—Y5-A2;
• wherein
• W2 is —CH2—, —O—, —N(H), —S—, —SO2—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO2—, —SO2N(H)—, —C(O)—O—, —NHSO2NH—, —O—S(O)2—, —O—CO—,
• wherein R19 and R20 are independently selected from the group consisting of:
• -hydrogen, -aryl, -alkyl, -alkylene-aryl, alkoxy, and -alkylene-O-aryl;
• R18 is -aryl, -alkyl, -alkylene-aryl, -alkylene-heteroaryl, or -alkylene-O-aryl;
• Y5 is a direct bond, —CH2—, —O—, —N(H), —S—, SO2—, —C(O)—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO2—, —SO2N(H)—, —C(O)—O—, —NHSO2NH—, —O—CO—,
• wherein R27 and R28 are independently selected from the group consisting of aryl, -alkyl, -alkylene-aryl, alkoxy, and alkyl-O-aryl;
• Y4 is
• a) -alkylene;
• b) -alkenylene;
• c) -alkynylene;
• d) -arylene;
• e) -heteroarylene;
• f) -cycloalkylene;
• g) -heterocyclylene;
• h) -alkylene-arylene;
• i) -alkylene-heteroarylene;
• j) -alkylene-cycloalkylene;
• k) -alkylene-heterocyclylene;
• l) -arylene-alkylene;
• m) -heteroarylene-alkylene;
• n) -cycloalkylene-alkylene;
• o) -heterocyclylene-alkylene;
• p) —O—;
• q) —S—;
• r) —(O)2—;
• or
• s) —S(O)—;
• wherein said alkylene groups may optionally contain one or more O, S, S(O), or SO2 atoms;
• A2 is
• a) heterocyclyl, fused arylheterocyclyl, or fused heteroarylheterocyclyl, containing at least one basic nitrogen atom, or
• b) -imidazolyl,
• R23, R24, and R25 are independently selected from the group consisting of:
• -hydrogen, -aryl, -heteroaryl, -alkylene-heteroaryl, alkyl, -alkylene-aryl, -alkylene-O-aryl, and -alkylene-O-heteroaryl;
• and R23 and R24 may be taken together to form a live membered ring having the formula —(CH2)3—X3—(CH2)r— bonded to the nitrogen atom to which R23 and R24 are attached
• wherein
• s and t are, independently, 1, 2, or 3;
• X3 is a direct bond, —CH2—, —O—, —S—, —S(O)2—, —C(O)—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO2—, —SO2N(H)—, —C(O)—O—, —O—C(O)—, —NHSO2NH—,
• wherein R28 and R29 are independently selected from the group consisting of:
• -hydrogen, -aryl, -heteroaryl, -alkyl, -arkylene-aryl, and -alkylene-heteroaryl;
• wherein
• the alkyl and/or aryl groups of R102 and R104 may be optionally substituted 1–4 times with a substituent group selected from the group consisting of:
• a) halogen;
• b) perhaloalkyl;
• c) alkyl;
• d) cyano:
• e) alkyloxy
• f) aryl;
• and
• g) aryloxy
• wherein the ring or rings containing a -hetercatom in the heteroaryl, heteroarylene, heterocyclyl, heterocyclene, fused arylheterocyclyl, or fused heteroarylheterocyclyl groups in R102 or R104 or in a substituent of R102 or R104 is a five membarnd nitrogen containing ring, and
• wherein
• at least one of R102 and R104 is a group of the formula
• —Y4 —NR23R24,
• —Y4 —NH−C(=NR25)NR23R24,
• —Y4 —C(=NR25)NR23R24, or
• —Y4 —Y5−A2,
• with the proviso that no more than one of R23, R24, and R25 is aryl or heteroaryl;
• or a pharmaceutically acceptable salt thereof.